Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

<tt>edgeR</tt> : a Bioconductor package for differential expression analysis of digital gene expression data

Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364

limma powers differential expression analyses for RNA-sequencing and microarray studies

Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458

ggplot2

Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 34,873

Integrative genomics viewer

Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390

ggplot2: Elegant Graphics for Data Analysis

Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688

Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.034 · Cited by 2,180

CAR immune cells: design principles, resistance and the next generation

Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 695

CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn

Albelda, S. Μ. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 561

T Cell Exhaustion

Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420

Epigenetic regulation of T cell exhaustion

Belk, J. A., Dániel, B., & Satpathy, A. T. (2022) · Nature Immunology · doi:10.1038/s41590-022-01224-z · Cited by 346

RASA2 ablation in T cells boosts antigen sensitivity and long-term function

Carnevale, J. C., Shifrut, E., Kale, N., Nyberg, W. A., Blaeschke, F., Chen, Y. Y., Li, Z., Bapat, S. P., Diolaiti, M. E., O’Leary, P. C., et al. (2022) · Nature · doi:10.1038/s41586-022-05126-w · Cited by 243

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

Hamilton, M. P., Sugio, T., Noordenbos, T., Shi, S., Bulterys, P. L., Liu, C. L., Kang, X., Olsen, M. N., Good, Z., Dahiya, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401361 · Cited by 223

CAR-T Therapies in Solid Tumors: Opportunities and Challenges

Guzman, G., Reed, M. R., Bielamowicz, K., Koss, B. S., & Rodriguez, A. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01380-x · Cited by 210

The Epigenetic Hallmarks of Cancer

Esteller, M., Dawson, M. A., Kadoch, C., Rassool, F. V., Jones, P. A., & Baylin, S. B. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0296 · Cited by 202

Clonal haematopoiesis and dysregulation of the immune system

Belizaire, R., Wong, W. J., Robinette, M. L., & Ebert, B. L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00843-3 · Cited by 161

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 170

Metabolic challenges and interventions in CAR T cell therapy

Peng, J.-J., Wang, L., Li, Z., Ku, C., & Ho, P. (2023) · Science Immunology · doi:10.1126/sciimmunol.abq3016 · Cited by 156

Methylation across the central dogma in health and diseases: new therapeutic strategies

Liu, R., Zhao, E., Yu, H., Yuan, C., Abbas, M. N., & Cui, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01528-y · Cited by 155

T cell dysfunction and therapeutic intervention in cancer

Zebley, C. C., Zehn, D., Gottschalk, S. M., & Chi, H. (2024) · Nature Immunology · doi:10.1038/s41590-024-01896-9 · Cited by 145

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy

Lei, T., Wang, Y., Zhang, Y., Yang, Y., Cao, J., Huang, J., Chen, J., Chen, H., Zhang, J., wang, L., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02444-y · Cited by 155

Clonal hematopoiesis: Mutation-specific adaptation to environmental change

Florez, M. A., Tran, B. T., Wathan, T. K., DeGregori, J., Pietras, E. M., & King, K. Y. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.05.006 · Cited by 129

Epigenome editing technologies for discovery and medicine

McCutcheon, S. R., Rohm, D., Iglesias, N., & Gersbach, C. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02320-1 · Cited by 130

Chromatin remodellers as therapeutic targets

Malone, H. A., & Roberts, C. W. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00978-5 · Cited by 119

Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

Xia, X., Yang, Z., Lu, Q., Liu, Z., Wang, L., Du, J., Li, Y., Yang, D., & Wu, S. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02079-8 · Cited by 112

CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia

Zebley, C. C., Brown, C., Tian, M., Fan, Y., Alli, S., Boi, S. K., Galletti, G., Lugli, E., Langfitt, D. M., Métais, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110079 · Cited by 109

CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors

Reed, S. C., Croessmann, S., & Park, B. H. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2598 · Cited by 112

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy

Li, N., Geng, S., Dong, Z., Jin, Y., Ying, H., Li, H., & Shi, L. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02032-9 · Cited by 109

CAR-T cells in solid tumors: Challenges and breakthroughs

Escobar, G., Berger, T. R., & Maus, M. V. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102353 · Cited by 114

Mechanisms of CAR T cell exhaustion and current counteraction strategies

Zhu, X., Li, Q., & Zhu, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1034257 · Cited by 106

Novel strategies for cancer immunotherapy: counter-immunoediting therapy

Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 107

Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy

Kang, T. G., Lan, X., Tian, M., Chen, H., Alli, S., Lim, S.-E., Bhatara, S., Vasandan, A. B., Ward, G., Bentivegna, S., et al. (2024) · Science · doi:10.1126/science.adl4492 · Cited by 103

Naturally occurring T cell mutations enhance engineered T cell therapies

Garcia, J. M., Daniels, J., Lee, Y., Zhu, I., Cheng, K., Liu, Q., Goodman, D. B., Burnett, C. E., Law, C., Thienpont, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07018-7 · Cited by 97

Disruption of SUV39H1 -Mediated H3K9 Methylation Sustains CAR T-cell Function

Jain, N., Zhao, Z., Koche, R. P., Antelope, C., Gozlan, Y., Montalbano, A., Brocks, D., Lopez, M., Dobrin, A., Shi, Y., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1319 · Cited by 95

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

Bulliard, Y., Andersson, B. S., Baysal, M. A., Damiano, J. S., & Tsimberidou, A. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01504-7 · Cited by 98

IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM

Ζαννίκου, Μ., Duffy, J. T., Levine, R., Seblani, M. D., Liu, Q., Presser, A., Arrieta, V. A., Chen, C. J., Sonabend, A. M., Horbinski, C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006239 · Cited by 93

Regulators of CD8+ T cell exhaustion

Sun, Q., & Dong, C. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01221-x · Cited by 91

Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion

Lamarche, C., Ward‐Hartstonge, K. A., Tian, M., Lin, D. T. S., Huang, Q. B., Brown, A., Edwards, K., Novakovsky, G., Qi, C. N., Kobor, M. S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219086120 · Cited by 87

Transcriptional and epigenetic regulators of human CD8+ T cell function identified through orthogonal CRISPR screens

McCutcheon, S. R., Swartz, A. M., Brown, M. C., Barrera, A., Amador, C. M., Siklenka, K., Humayun, L. L., ter Weele, M. A., Isaacs, J. M., Reddy, T. E., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01554-0 · Cited by 89

Cellular and molecular waypoints along the path of T cell exhaustion

Lan, X., Zebley, C. C., & Youngblood, B. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg3868 · Cited by 87

Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells

Mai, D., Johnson, O., Reff, J., Fan, T., Scholler, J., Sheppard, N. C., & June, C. H. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218632120 · Cited by 86

CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence

Wei, W., Chen, Z., & Wang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512317 · Cited by 90

Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway

Zhu, M., Han, Y., Gu, T., Wang, R. Y., Si, X., Kong, D., Zhao, P., Wang, X., Li, J., Zhai, X., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114065 · Cited by 90

The SWI/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8+ T cells

Baxter, A. E., Huang, H., Giles, J. R., Chen, Z., Wu, J. E., Drury, S., Tuite-Dalton, K. A., Park, S. L., Torres, L., Simone, B. W., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.05.008 · Cited by 83

Clonal hematopoiesis and inflammation – the perpetual cycle

Avagyan, S., & Zon, L. I. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.12.001 · Cited by 79

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 84

Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion

Battistello, E., Hixon, K., Comstock, D. E., Collings, C. K., Chen, X., Rodriguez-Hernaez, J., Lee, S., Cervantes, K. S., Hinkley, M. M., Ntatsoulis, K., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.02.026 · Cited by 78

Systematic profiling reveals betaine as an exercise mimetic for geroprotection

Geng, L., Ping, J., Wu, R., Yan, H., Zhang, H., Zhuang, Y., Ning, T., Wang, J., Liang, C., Zhang, J., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.001 · Cited by 75

SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors

López-Cobo, S., Fuentealba, J. R., Gueguen, P., Bonté, P.-E., Tsalkitzi, K., Chacón, I., Glauzy, S., Bohineust, A., Biquand, A., Silva, L., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1350 · Cited by 72

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors

Chen, Q., Lu, L., & Ma, W. (2022) · Cancers · doi:10.3390/cancers14235983 · Cited by 73

Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors

Ahn, T., Bae, E., & Seo, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.004 · Cited by 71

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies

Huang, J., Huang, X., & Huang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019115 · Cited by 72

Modular pooled discovery of synthetic knockin sequences to program durable cell therapies

Blaeschke, F., Chen, Y. Y., Apathy, R., Dániel, B., Chen, A. Y., Chen, P. A., Sándor, K., Zhang, W., Li, Z., Mowery, C. T., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.013 · Cited by 71

Impact of epigenetic reprogramming on antitumor immune responses in glioma

McClellan, B. L., Haase, S., Núñez, F. J., Alghamri, M. S., Dabaja, A. A., Lowenstein, P. R., & Castro, M. G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163450 · Cited by 68

Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells

Glaser, V., Flugel, C., Kath, J., Du, W., Drosdek, V., Franke, C., Stein, M., Pruß, A., Schmueck-Henneresse, M., Volk, H.-D., et al. (2023) · Genome biology · doi:10.1186/s13059-023-02928-7 · Cited by 65

Mechanisms of T cell exhaustion guiding next-generation immunotherapy

Zebley, C. C., & Youngblood, B. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.04.004 · Cited by 65

Fueling CARs: metabolic strategies to enhance CAR T-cell therapy

der Vreken, A. V., Vanderkerken, K., Bruyne, E. D., Veirman, K. D., Breckpot, K., & Menu, E. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00535-1 · Cited by 61

Molecular Mechanisms Governing CD8 T Cell Differentiation and Checkpoint Inhibitor Response in Cancer

Rausch, L., & Kallies, A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082223-044122 · Cited by 66

The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy

Micevic, G., Bosenberg, M., & Yan, Q. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0784 · Cited by 60

Engineering chimeric antigen receptor T cells for solid tumour therapy

Liu, L., Qu, Y., Cheng, L., Yoon, C. W., He, P., Monther, A., Guo, T., Chittle, S. J., & Wang, Y. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1141 · Cited by 61

Optimizing the manufacturing and antitumour response of CAR T therapy

Liu, Y., Sperling, A. S., Smith, E. L., & Mooney, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00031-x · Cited by 60

Antitumor progenitor exhausted CD8+ T cells are sustained by TCR engagement

Lan, X., Tian, M., Alli, S., Guy, C. S., Djekidel, M. N., Liu, X., Boi, S. K., Chowdhury, P. S., He, M.-H., Zehn, D., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01843-8 · Cited by 59

Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics

Zhong, F., Lin, Y., Zhao, L., Yang, C., Ye, Y., & Shen, Z. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02292-0 · Cited by 58

Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy

Lu, Y., & Fu, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02334-6 · Cited by 58

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

Vo, M.-C., Tran, V.-D.-H., Nguyen, V., Ruzimurodov, N., Trung, D. T., Kim, S. K., Jung, S., & Lee, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01744-9 · Cited by 59

Strategies to reinvigorate exhausted CD8+ T cells in tumor microenvironment

Guan, Q., Han, M., Guo, Q., Yan, F., Wang, M., Ning, Q., & Xi, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1204363 · Cited by 57

Integration of ζ-deficient CARs into the CD3 ζ gene conveys potent cytotoxicity in T and NK cells

Kath, J., Franke, C., Drosdek, V., Du, W., Glaser, V., Fuster‐García, C., Stein, M., Zittel, T., Schulenberg, S., Porter, C. E., et al. (2024) · Blood · doi:10.1182/blood.2023020973 · Cited by 52

Regulatory T-cell therapy approaches

McCallion, O., Bilici, M., Hester, J., & Issa, F. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac078 · Cited by 52

IL-7R licenses a population of epigenetically poised memory CD8 + T cells with superior antitumor efficacy that are critical for melanoma memory

Micevic, G., Daniels, A., Karlsen, K. F., Park, K., Talty, R., McGeary, M. K., Mirza, H., Blackburn, H. N., Sefik, E., Cheung, J. F., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2304319120 · Cited by 49

Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models

Talbot, L. J., Chabot, A., Ross, A. B., Beckett, A., Nguyen, P., Fleming, A. M., Chockley, P. J., Sheppard, H., Wang, J., Gottschalk, S. M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3298 · Cited by 48

ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights

Ali, A. M., & DiPersio, J. F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1432799 · Cited by 50

Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma

Canedo, G. D. O., Roddie, C., & Amrolia, P. J. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013586 · Cited by 47

T cell-based cancer immunotherapy: opportunities and challenges

Ma, K., Xu, Y., Cheng, H., Tang, K., Ma, J., & Huang, B. (2025) · 中国科学通报：英文版 · doi:10.1016/j.scib.2025.03.054 · Cited by 47

Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling

Bell, M. R., Lange, S., Sejdiu, B. I., Ibañez-Vega, J., Shi, H., Sun, X., Meng, X., Nguyen, P., Sutton, M. T., Wagner, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01143-w · Cited by 45

Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches

Gu, T., Zhu, M., Huang, H., & Hu, Y. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200256 · Cited by 45

Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy

Ottaviano, G., & Qasim, W. (2025) · Leukemia · doi:10.1038/s41375-025-02585-8 · Cited by 45

RNA Therapeutics for Improving CAR T-cell Safety and Efficacy

Schaible, P., Bethge, W. A., Lengerke, C., & Haraszti, R. Á. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2155 · Cited by 43

IL-4 drives exhaustion of CD8+ CART cells

Stewart, C. M., Siegler, E. L., Sakemura, R. L., Cox, M. J., Huynh, T., Kimball, B. L., Mai, L., Can, İ., Roman, C. M., Yun, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51978-3 · Cited by 43

Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment

von Beck, K., von Beck, T. A., Ferrell, P. B., Bick, A. G., & Kishtagari, A. (2023) · Blood Cancer Journal · doi:10.1038/s41408-022-00773-8 · Cited by 45

Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy

Singh, N., & Maus, M. V. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.010 · Cited by 44

Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review

Moradi, V., Khodabandehloo, E., Alidadi, M., Omidkhoda, A., & Ahmadbeigi, N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1388475 · Cited by 42

Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects

Qin, H., Zhou, Z., Shi, R., Mai, Y., Xu, Y., Fu, P., Cheng, G., Zhang, Z., Chen, W., Chen, Y., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01701-6 · Cited by 43

Clonal hematopoiesis: Molecular and clinical implications

Kusne, Y. N., Xie, Z., & Patnaik, M. M. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106787 · Cited by 43

Tracing the development of CAR-T cell design: from concept to next-generation platforms

Alsaieedi, A., & Zaher, K. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1615212 · Cited by 49

Developmental origins shape the paediatric cancer genome

Chen, X., Yang, W., Roberts, C. W. M., & Zhang, J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00684-9 · Cited by 49

TET2 regulates early and late transitions in exhausted CD8 + T cell differentiation and limits CAR T cell function

Dimitri, A. J., Baxter, A. E., Chen, G. M., Hopkins, C. R., Rouin, G. T., Huang, H., Kong, W., Holliday, C., Wiebking, V., Bartoszek, R. L., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp9371 · Cited by 42

The development of CD8 T-cell exhaustion heterogeneity and the therapeutic potentials in cancer

Zhang, J., Lei, F., & Tan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166128 · Cited by 39

Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy

Frlic, T., & Pavlin, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688995 · Cited by 38

CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors

Liu, J., Jiao, X., Ma, D., Fang, Y., & Gao, Q. (2024) · Med · doi:10.1016/j.medj.2024.03.001 · Cited by 35

Epigenetic regulation of T cell exhaustion in cancer

Kang, T. G., Johnson, J. T., Zebley, C. C., & Youngblood, B. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00883-y · Cited by 36

Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction

Jung, I.-Y., Bartoszek, R. L., Rech, A. J., Collins, S. M., Ooi, S., Williams, E. F., Hopkins, C. R., Narayan, V., Haas, N. B., Frey, N. V., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1175 · Cited by 35

Single-cell analysis of acute lymphoblastic and lineage-ambiguous leukemia: approaches and molecular insights

Iacobucci, I., Witkowski, M. T., & Mullighan, C. G. (2022) · Blood · doi:10.1182/blood.2022016954 · Cited by 34

Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma

Herzberg, C., Schiele, P., Walter, A. L., Hamm, F., Obermayer, B., Kath, J., Busch, D., Stroux, A., Frick, M., Penack, O., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010709 · Cited by 36

Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers

Pirouzbakht, M., Hamzeh, S., & Samarkhazan, H. S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01902-w · Cited by 34

Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome

Salz, L., Seitz, A., Schaefer, D., Franzen, J., Holzer, T., García-Prieto, C. A., Bürger, I., Hardt, O., Esteller, M., & Wagner, W. (2023) · Leukemia · doi:10.1038/s41375-023-01966-1 · Cited by 35

Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells

Qiu, F., Jiang, P., Zhang, G., An, J., Ruan, K., Lyu, X., Zhou, J., & Sheng, W. (2024) · Nature Communications · doi:10.1038/s41467-024-48607-4 · Cited by 35

Integrated epigenetic and genetic programming of primary human T cells

Goudy, L., Ha, A. S., Borah, A. A., Umhoefer, J. M., Chow, L., Tran, C., Winters, A., Talbot, A., Hernandez, R., Li, Z., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02856-w · Cited by 38

Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance

García-Robledo, J. E., Cabrera-Salcedo, S. C., Brandauer, A. M., Romano, F., Rengifo-Martinez, J., Toro-Pedroza, A., Hincapie, J. S. V., Ríos-Serna, L. J., Loukanov, A. R., Cardona, A. F., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1698442 · Cited by 32

Cytokine signaling in chimeric antigen receptor T-cell therapy

Kagoya, Y. (2023) · International Immunology · doi:10.1093/intimm/dxad033 · Cited by 31

CAR-engineered cell therapies: current understandings and future perspectives

Bayat, M., & Nahand, J. S. (2026) · Molecular Biomedicine · doi:10.1186/s43556-025-00401-4 · Cited by 33

New target DDR1: A “double-edged sword” in solid tumors

Tian, Y., Bai, F., & Zhang, D. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188829 · Cited by 32

Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance

Qin, Y., & Xu, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1053120 · Cited by 32

Clonal hematopoiesis and differential outcomes after immune checkpoint blockade

Hsiehchen, D., Sfreddo, H. J., Zhao, K., Han, C. Y., & Morris, L. G. T. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.024 · Cited by 32

Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface

Buttigieg, M. M., & Rauh, M. J. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00132 · Cited by 30

GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells

Ibañez-Vega, J., Hebbar, N., Thanekar, U., Yi, Z., Houke, H., Ward, M. B., Nevitt, C. D., Tian, L., Mack, S. C., Sheppard, H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101297 · Cited by 29

DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells

Ramabadran, R., Wang, J. H., Reyes, J. M., Guzman, A. G., Gupta, S., Rosas, C., Brunetti, L., Gundry, M. C., Tovy, A., Long, H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01109-9 · Cited by 33

Coengineering specificity, safety, and function into T cells for cancer immunotherapy

Attianese, G. M. P. G., Ash, S., & Irving, M. B. (2023) · Immunological Reviews · doi:10.1111/imr.13252 · Cited by 29

De novo DNA methylation programs regulate CAR T-cell exhaustion

Zebley, C. C., Petersen, C. T., Prinzing, B. L., Bell, M. R., Fan, Y., Crawford, J. C., Houke, H., Haydar, D., Yi, Z., Nguyen, P., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.204.supp.246.5 · Cited by 5

De novo DNA methylation programs regulate T cell exhaustion and limit T cell-based immunotherapies

Youngblood, B., Ghoneim, H. E., Abdelsamed, H. A., Moustaki, A., Fan, Y., Crawford, J. C., Thomas, P. G., Stewart, E. S., & Federico, S. M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.202.supp.134.14 · Cited by 3

CAR T cells need a pitstop to win the race

Zebley, C. C., & Youngblood, B. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.011 · Cited by 5

Abstract 61: Transient "rest" reinvigorates exhausted CAR T cells via epigenetic remodeling

Weber, E. W., & Mackall, C. L. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-61

Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling

Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., Good, Z., Belk, J. A., Dániel, B., Klysz, D. D., et al. (2021) · Science · doi:10.1126/science.aba1786 · Cited by 653